BRONCHOGEN

Tissue Repair & HealingResearch Only

Very limited research base with only animal and cell culture studies. Interesting concept but far too early to draw meaningful conclusions about effectiveness.

Primarily studied by researchers investigating peptide bioregulators and respiratory aging, particularly those following Khavinson's bioregulator research methodology.

FDA Status

Research Only

Since Feb 2026

Evidence

Limited data

Studies

7 total

What is BRONCHOGEN?

Part of the Khavinson bioregulator family, this tripeptide (Ala-Glu-Asp) targets respiratory and bronchial tissues specifically. Researchers investigate it primarily for understanding how short peptides might influence lung tissue maintenance and repair processes, especially in the context of aging-related respiratory changes.

This tripeptide appears to enter cell nuclei and bind directly to specific DNA sequences in bronchial epithelial cells, influencing which genes get activated. Rather than acting like a hormone or growth factor, it seems to work more like a molecular switch, turning on genes involved in tissue repair and protective mucus production in the respiratory tract.

What the Research Shows

All 7 studies were conducted in laboratory settings using cell cultures or animal models, with no human clinical trials completed to date.

There are no human studies or randomized controlled trials of BRONCHOGEN; all 7 studies identified were conducted in cell cultures or animal models, showing effects including reduced lung inflammation and bronchial epithelium restoration in a COPD model, DNA-stabilizing properties, and peptide penetration into cell nuclei with specific DNA interactions.